Florida Pharmacy Shut for Prescription Free-for-All
Published Date: 7/14/2025
Notice
Summary
Webb's Square Pharmacy in Florida lost its DEA license because it gave out controlled medicines without proper prescriptions from July 2021 to March 2024. The pharmacy didn’t respond to the government’s warnings, so their registration was suspended and then revoked to protect public safety. This means they can’t legally handle controlled drugs anymore, effective immediately, impacting their business and customers.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Pharmacy
The Drug Enforcement Administration revoked DEA Certificate of Registration No. FJ2231570 issued to JYA LLC d/b/a Webb's Square Pharmacy. The Order also denies any pending application to renew or modify that registration or any other pending registration applications for JYA LLC in Florida; the Order is effective August 13, 2025.
Immediate Suspension Issued Nov 18, 2024
On November 18, 2024, the DEA issued an Order to Show Cause and Immediate Suspension of Registration that immediately suspended Certificate No. FJ2231570 under 21 U.S.C. 824(d). The OSC/ISO alleges the pharmacy dispensed controlled substances without valid prescriptions between on or about July 31, 2021 and March 28, 2024.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Previous / Next Documents
Previous: 2025-13119, Elias Garcia Garcia, P.A.; Decision and Order
Elias Garcia Garcia, P.A., a medical professional in Arizona, lost the right to handle controlled substances because he no longer has state permission to do so. The DEA tried to notify him, but he didn’t ask for a hearing, so his registration was revoked by default. This means he can’t legally prescribe or dispense certain drugs anymore, effective immediately.
Next: 2025-13122, Just Here II Pharmacy; Decision and Order
Just Here II Pharmacy in Philadelphia lost its DEA registration because it didn’t keep proper records of controlled substances, making it unsafe for the public. The pharmacy’s registration was suspended immediately and then officially revoked by the DEA, even though their registration expired at the end of 2024. This means Just Here II can no longer handle controlled drugs, protecting community safety.